Nuvation Bio has updated investors with the good news of a European partnership, to sell newly FDA approved and commercialized drug Ibtrozi in Europe and other countries outside of the US, for patients with Ros1 NSCLC. Like many other US based companies, they utilize partnerships outside the US who already have a footprint of sales professionals actively selling similar products in the field. Under this agreement completed today with Eisai, there is upfront, milestones and a royalty kick back to the owner of the product, in this case Nuvation Bio. The selling partner reaps the revenue abroad. A win / win cost effective scenario. Below are the Royalty agreements that are now in place outside of the US for Nuvation Bio (NUVB).
China: Innovent
Biologics
(Dovbleron) First and second-line approval.
(Dovbleron) First and second-line approval.
-Milestone
payments up to $189 million
-Tiered royalty
payments based on annual net sales of Taletrectinib
-60 million upfront
-170 million milestone payments
-10% to 19% tiered royalty payments from net sales of Taletrectinib
Japan: Nippon Kayaku
-Milestone payments based on domestic sales exceeding certain amounts
-Milestone payments based on domestic sales exceeding certain amounts
-Royalty based on domestic net sales
No comments:
Post a Comment